In a clinical trial, CD22 CAR-T cells demonstrated an 80% response rate (24/30 patients) in the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia, providing a valuable window of time for subsequent hematopoietic stem cell transplantation (63). Here, CD22 is linked to B-cell acute lymphoblastic leukemia.